drugset

drugset / Trial / NCT03075241

Z-Drugs for Sleep Disorders in Alzheimer's Disease

NCT03075241 ↗

Phase 3 Completed 62 enrolled Brasilia University Hospital

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether Zolpidem and Zoplicone are efective in the treatment of sleep disorders in Alzheimer's disease (AD)

Timeline

Start: 2016-10
Primary completion: 2020-04
Completion: 2020-04

Publications

Louzada LL, Machado FV, Quintas JL, Ribeiro GA, Silva MV, Mendonca-Silva DL, Goncalves BSB, Nobrega OT, Camargos EF. The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial. Neuropsychopharmacology. 2022 Jan;47(2):570-579. doi: 10.1038/s41386-021-01191-3. Epub 2021 Oct 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zolpidem	Small molecule	10 mg	—
Subject	Zopiclone	Small molecule	7.5 mg	—

Indications